Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
01/10/17
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
02/15/17SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/14/17SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/10/17SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/07/17SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
01/25/17SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
02/16/17Pacira Pharmaceuticals Announces Timing for 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2016 will be released before the market opens on Wednesday, March 1, 2017. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, March 1, 2017, at 8:30 a.m. ET. The call can be accessed by dialing 1-877-845-0... 
Printer Friendly Version
02/15/17Pacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets’ Healthcare Conference
PARSIPPANY, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Pacira Pharmaceuticals management team is scheduled to participate in an analyst-led fireside chat at the 2017 RBC Capital Markets’ Healthcare Conference at 10:00 a.m. ET on Wednesday, February 22, 2017, in New York. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A... 
Printer Friendly Version
01/25/17Pacira Pharmaceuticals Announces Collaboration with DePuy Synthes to Support Promotion, Education and Training of EXPAREL® in Orthopedics
– Collaboration will focus on opportunities in joint reconstruction, spine, sports medicine and trauma specialties – – Conference call today at 8:30 a.m. ET – PARSIPPANY, N.J., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the initiation of an agreement with DePuy Synthes Sales Inc. to market and promote the use of EXPAREL® (bupivacaine liposome injectable suspension) for orthopedic procedures in the United States market. With the opioid epid... 
Printer Friendly Version
01/06/17Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million
EXPAREL net product sales driven by soft tissue and orthopedic procedures PARSIPPANY, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported preliminary unaudited total revenues and EXPAREL® (bupivacaine liposome injectable suspension) net product sales for the fourth quarter and full-year 2016.  “2016 was a year of solid execution that has set the stage for continued growth of EXPAREL,” said Dave Stack, chief executive officer and chairman of Pac... 
Printer Friendly Version
01/03/17Pacira Pharmaceuticals, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference at 3:30 p.m. PT (6:30 p.m. ET) on Monday, January 9, 2017, in San Francisco. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investo... 
Printer Friendly Version
11/29/16Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction
Collaboration will leverage genetic testing to identify patients predisposed to developing addiction following opioid exposure PARSIPPANY, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a patient-specific opioid risk assessment program that includes behavioral surveys, educational tools and genetic testing. U... 
Printer Friendly Version
11/22/16American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives
Pacira grant will allow for the development and distribution of resources to educate patients and surgeons on opioid use in surgical care CHICAGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- The American College of Surgeons (ACS) today announced a new multifaceted initiative to improve the knowledge and management of pain in surgical patients with a focus on opioid risk and non-opioid alternatives. With an educational grant from Pacira Pharmaceuticals, Inc. (Pacira), ACS will develop Opioids and Sur... 
Printer Friendly Version
11/11/16Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL® in Total Knee Replacement Surgery
3D Mobile Simulation Will Also Debut in Pacira Booth #907 at AAHKS 2016 PARSIPPANY, N.J., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today introduced a revolutionary new virtual reality simulation intended to provide clinicians with an immersive, hands-on training experience to reinforce the recommended technique for administering EXPAREL (bupivacaine liposome injectable suspension) in total knee arthroplasty (TKA) based on the infiltration protocol developed... 
Printer Friendly Version
11/10/16Correction: Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (9:00 a.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
11/10/16Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (7:00 p.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
>> Access Older Press Releases
Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com